Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
The advent of direct-acting antivirals (DAAs) has provided the impetus to transplant kidneys from hepatitis C virus-positive donors into uninfected recipients (D+/R-). Thirty D+/R- patients received DAA treatment. Sustained virologic response (SVR12) was defined as an undetectable viral load in 12 weeks after treatment. An age-matched cohort of uninfected donor and recipient pairs (D-/R-) transplanted during same time period was used for comparison. The median day of viral detection was postoperative day (POD) 2. The detection of viremia in D+/R- patients was 100%. The initial median viral load was 531 copies/μL (range: 10-1 × 108 copies/μL) with a median peak viral load of 3.4 × 105 copies/μL (range: 804-1.0 × 108 copies/μL). DAAs were initiated on median POD 9 (range: 5-41 days). All 30 patients had confirmed SVR12. During a median follow-up of 10 months, patient and graft survival was 100%, and acute rejection was 6.6% with no major adverse events related to DAA treatment. Delayed graft function was significantly decreased in D+/R- patients as compared to the age-matched cohort (27% vs 60%; P = .01). D+/R- transplantation offers patients an alternative strategy to increase access.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Clinical transplantation - 34(2020), 4 vom: 01. Apr., Seite e13833 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Graham, Jay A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 23.06.2021 Date Revised 23.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ctr.13833 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306666413 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306666413 | ||
| 003 | DE-627 | ||
| 005 | 20231225123857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ctr.13833 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306666413 | ||
| 035 | |a (NLM)32072689 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Graham, Jay A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2021 | ||
| 500 | |a Date Revised 23.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a The advent of direct-acting antivirals (DAAs) has provided the impetus to transplant kidneys from hepatitis C virus-positive donors into uninfected recipients (D+/R-). Thirty D+/R- patients received DAA treatment. Sustained virologic response (SVR12) was defined as an undetectable viral load in 12 weeks after treatment. An age-matched cohort of uninfected donor and recipient pairs (D-/R-) transplanted during same time period was used for comparison. The median day of viral detection was postoperative day (POD) 2. The detection of viremia in D+/R- patients was 100%. The initial median viral load was 531 copies/μL (range: 10-1 × 108 copies/μL) with a median peak viral load of 3.4 × 105 copies/μL (range: 804-1.0 × 108 copies/μL). DAAs were initiated on median POD 9 (range: 5-41 days). All 30 patients had confirmed SVR12. During a median follow-up of 10 months, patient and graft survival was 100%, and acute rejection was 6.6% with no major adverse events related to DAA treatment. Delayed graft function was significantly decreased in D+/R- patients as compared to the age-matched cohort (27% vs 60%; P = .01). D+/R- transplantation offers patients an alternative strategy to increase access | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a donor-derived infections | |
| 650 | 4 | |a donors and donation | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a infection and infectious agents | |
| 650 | 4 | |a kidney disease | |
| 650 | 4 | |a viral | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Torabi, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Ajaimy, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Akalin, Enver |e verfasserin |4 aut | |
| 700 | 1 | |a Liriano, Luz E |e verfasserin |4 aut | |
| 700 | 1 | |a Azzi, Yorg |e verfasserin |4 aut | |
| 700 | 1 | |a Pynadath, Cindy |e verfasserin |4 aut | |
| 700 | 1 | |a Greenstein, Stuart M |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Doctor Y |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Amy S |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Jeffery M |e verfasserin |4 aut | |
| 700 | 1 | |a Powell, Tia P |e verfasserin |4 aut | |
| 700 | 1 | |a Reinus, John F |e verfasserin |4 aut | |
| 700 | 1 | |a Kinkhabwala, Milan M |e verfasserin |4 aut | |
| 700 | 1 | |a Rocca, Juan P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical transplantation |d 1987 |g 34(2020), 4 vom: 01. Apr., Seite e13833 |w (DE-627)NLM07493306X |x 1399-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:4 |g day:01 |g month:04 |g pages:e13833 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ctr.13833 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 4 |b 01 |c 04 |h e13833 | ||